References

British National Formulary. Fluconazole. 2024a. https//bnf.nice.org.uk/drugs/fluconazole/indications-and-dose (accessed 11 June 2024)

British National Formulary. Amphotericin B. 2024b. https//bnf.nice.org.uk/drugs/amphotericin-b (accessed 11 June 2024)

British National Formulary. Antifungals, systemic use. 2024c. https//bnf.nice.org.uk/treatment-summaries/antifungals-systemic-use (accessed 11 June 2024)

British National Formulary. Micafungin. 2024d. https//bnf.nice.org.uk/drugs/micafungin (accessed 11 June 2024)

Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections. Infect Dis Ther. 2021; 10:115-147 https://doi.org/10.1007/s40121-020-00382-7

DrugBank Online. Micafungin. 2024. https//go.drugbank.com/drugs/DB01141 (accessed 11 June 2024)

Pristov KE, Ghannoum MA Resistance of Candida to azoles and echinocandins worldwide. Clinical Microbiology and Infection. 2019; 25:(7)792-798 https://doi.org/10.1016/j.cmi.2019.03.028

World Health Organization. WHO fungal priority pathogens list to guide research, development and public health action. 2022. https//www.who.int/publications/i/item/9789240060241 (accessed 11 June 2024)

Zhang Z, Bills GF, An Z Advances in the treatment of invasive fungal disease. PLoS Pathogens. 2023; 19:(5) https://doi.org/10.1371/journal.ppat.1011322

World Health Organization fungal priority pathogens list

02 July 2024
Volume 6 · Issue 7

Check your answers on page 306https://doi.org/10.12968/jprp.2024.6.7.282

In 2022, the World Health Organization (WHO) published its first fungal priority pathogens list in response to the increase of invasive fungal disease globally (WHO, 2022). This was the first report to categorise fungal pathogens in order to focus and prioritise an international and concentrated public health response to fungal infections and antifungal resistance. With over 300 million severe cases and 1.5 million deaths annually, invasive fungal diseases are a source of global morbidity and mortality, and are a significant burden on finite medical resources (Zhang et al, 2023).

Most pathogenic fungi are opportunistic and cause disease in those who are immunocompromised. This includes people with an underlying condition such as HIV infection, those undergoing chemotherapy for the treatment of cancers or long-term immune suppressive drug therapy following transplantation surgery. Concurrently, there is a rise in the incidence of invasive fungal diseases due to the limited systemic antifungal therapies available.

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month